Suggested remit - To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for unresectable, advanced oesophageal cancer when standard chemotherapy has failed.
 
Status In progress
Process STA 2018
ID number 1249

Provisional Schedule

Expected publication 15 June 2021

Project Team

Project lead Shonagh D'Sylva

Email enquiries

Evidence Review Group / Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter

Consultees

Companies sponsors Bristol-Myers Squibb (nivolumab)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups no patient or carer groups were able to take part in this appraisal
Professional groups Association of Cancer Physicians
  British Association of Surgical Oncology
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (docetaxel, irinotecan, paclitaxel) – not participating
  Celgene (paclitaxel)
  Genzyme Therapeutics (docetaxel) – not participating
  Hospira UK (docetaxel, irinotecan, paclitaxel) – not participating
  Medac (docetaxel, irinotecan paclitaxel) – not participating
  Pfizer (irinotecan) – not participating
  Seacross Pharmaceuticals (docetaxel, irinotecan) – not participating
  Servier Laboratories (irinotecan) – not participating
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
13 May 2021 - 28 May 2021 Final appraisal document: 1
05 January 2021 Committee meeting: 2
04 November 2020 - 25 November 2020 Appraisal consultation: 1
13 October 2020 Committee meeting: 1
13 February 2020 Invitation to participate
28 November 2019 The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab for previously treated oesophageal cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid-February 2020 when we will write to you about how you can get involved.
25 September 2019 - 16 October 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 2
12 July 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab for previously treated oesophageal cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid- November 2019 when we will write to you about how you can get involved.
22 March 2019 In progress. As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab for previously treated oesophageal cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid- August 2019 when we will write to you about how you can get involved.
25 January 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab for previously treated oesophageal cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid- March 2019 when we will write to you about how you can get involved.
06 July 2018 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nivolumab for previously treated oesophageal cancer. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early December 2018.
06 February 2018 - 06 March 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
11 August 2017 In progress. In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance